Cargando…
Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial
BACKGROUND: Liraglutide is a glucose-lowering medication used to treat type 2 diabetes and obesity. It is a GLP-1 receptor agonist with downstream metabolic changes beyond the incretin system, such as reducing the risk of cardiovascular complications. The understanding of these changes is critical f...
Autores principales: | Wretlind, Asger, Zobel, Emilie Hein, de Zawadzki, Andressa, Ripa, Rasmus Sejersten, Curovic, Viktor Rotbain, von Scholten, Bernt Johan, Mattila, Ismo Matias, Hansen, Tine Willum, Kjær, Andreas, Vestergaard, Henrik, Rossing, Peter, Legido-Quigley, Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012104/ https://www.ncbi.nlm.nih.gov/pubmed/36992761 http://dx.doi.org/10.3389/fcdhc.2022.856485 |
Ejemplares similares
-
Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial
por: Zobel, Emilie H, et al.
Publicado: (2021) -
Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials
por: Wretlind, Asger, et al.
Publicado: (2023) -
Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [(64)Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial
por: Jensen, Jacob K., et al.
Publicado: (2021) -
Effect of liraglutide on expression of inflammatory genes in type 2 diabetes
por: Zobel, Emilie H., et al.
Publicado: (2021) -
Effect of Liraglutide on Vascular Inflammation Evaluated by [(64)Cu]DOTATATE
por: Zobel, Emilie H., et al.
Publicado: (2021)